6533b85bfe1ef96bd12bab81
RESEARCH PRODUCT
Erythropoietin and Myocardial Infarction
Giuseppe LippiFabian Sanchis-gomarVladimir E. Martínez-bellosubject
Maleendocrine systemmedicine.medical_specialtyMyocardial InfarctionAMI.General Biochemistry Genetics and Molecular BiologyText mininghemic and lymphatic diseasesInternal medicineAnimalsHumansMedicineMyocardial infarctionGeneral Pharmacology Toxicology and PharmaceuticsErythropoietinreproductive and urinary physiologyResearch ArticlesErythropoietin; myocardial infarction; AMI.Ventricular Remodelingurogenital systembusiness.industryGeneral NeuroscienceGeneral Medicinemedicine.diseaseErythropoietinCardiologybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugdescription
Erythropoietin (EPO) has the potential to improve ischemic tissue by mobilizing endothelial progenitor cells and enhancing neovascularization. We hypothesized that combining EPO with human chorionic gonadotrophin (hCG) would improve post–myocardial infarction (MI) effects synergistically.
year | journal | country | edition | language |
---|---|---|---|---|
2012-01-04 | Clinical and Translational Science |